ZURICH (Reuters) – Roche’s cobas SARS-CoV-2 Test has received U.S. authorisation for testing individuals without symptoms or reasons to suspect a COVID-19 infection, the Swiss drugmaker said on Tuesday.
“The high-throughput, highly sensitive cobas SARS-CoV-2 Test under FDA Emergency Use Authorisation can now be used to test individual or pooled samples from people without symptoms or other reasons to suspect COVID-19,” Roche said in a statement.
(Reporting by Brenna Hughes Neghaiwi; Editing by Riham Alkousaa)
